DNDN Management expects 2013 Provenge sales to surpass 2012 sales
Management stated in its first quarter 2013 conference call that Provenge sales will rebound in the coming quarters. The company expects its second quarter Provenge sales in the mid-$70 million range. The company also believes that 2013 Provenge sales are expected to surpass the 2012 sales figure of $325 million. L
EU approval doubles sales. Will hit break even next 2 quarters is my guess. New products in pipeline, and more approvals around the world. Looking at $2-3 Billion/year just on provenge. Price target = $80/share ! DO NOT SELL YOUR SHARES !